STOCK TITAN

VectivBio Publishes Invitation to the Extraordinary General Meeting

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

VectivBio Holding AG (Nasdaq: VECT) announced its Extraordinary General Meeting scheduled for September 2, 2021. The sole agenda item is the election of Paul R. Carter and Dr. Murray W. Stewart to the Board of Directors. Due to COVID-19, the meeting will not allow personal attendance; shareholders must use an independent proxy for representation. VectivBio is focused on developing treatments for severe rare conditions, with apraglutide as its lead candidate currently in a Phase 3 trial for short bowel syndrome.

Positive
  • Election of experienced board members may enhance governance.
  • Ongoing Phase 3 clinical trial of apraglutide could lead to future market approval.
Negative
  • Meeting restrictions due to COVID-19 may limit shareholder engagement.
  • Dependence on the success of apraglutide raises risk for investors.

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions, today published the invitation to the Extraordinary General Meeting, which will be held on Thursday, September 2, 2021, at 2:00 p.m. CEST / 8:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland.

As previously announced, the sole agenda item of the Extraordinary General Meeting is the election of Paul R. Carter and Dr. Murray W. Stewart as new members of the Board of Directors.

In view of the ongoing special situation involving the COVID-19 pandemic, and in accordance with Ordinance 3 of the Swiss Federal Council regarding measures on combatting the coronavirus (COVID-19), the Extraordinary General Meeting will take place without the personal attendance of shareholders. Shareholders shall be represented at the Extraordinary General Meeting exclusively by the independent proxy. For information on how to issue voting instructions to the independent proxy, shareholders can access the invitation to the Extraordinary General Meeting at www.edocumentview.com/VECT.

About VectivBio AG
VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions. VectivBio is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s lead product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal diseases. Apraglutide is currently being evaluated in a global Phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure. VectivBio also plans to initiate clinical studies of apraglutide in additional indications, including graft versus host disease, where GLP-2 is believed to be central to disease pathophysiology.

Forward Looking Statement
Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements concerning the timing of the Extraordinary General Meeting. Such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the impacts of the ongoing COVID-19 pandemic and those risks and uncertainties identified in the “Risk Factors” section of VectivBio’s Registration Statement on Form F-1 declared effective by the Securities and Exchange Commission on April 8, 2021 and its other subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

For more information visit www.vectivbio.com, and follow us on LinkedIn.

Investors
Graham Morrell
graham.morrell@vectivbio.com

Media
Morgan Warners
+1 (202) 295 0124
morgan.warners@fgh.com


FAQ

What is the date of VectivBio's Extraordinary General Meeting?

The Extraordinary General Meeting is scheduled for September 2, 2021.

Who is being elected to the Board of Directors at VectivBio?

Paul R. Carter and Dr. Murray W. Stewart are the candidates for election.

How will shareholders participate in the VectivBio meeting?

Shareholders can participate by voting through an independent proxy due to COVID-19 restrictions.

What is VectivBio's lead product candidate?

VectivBio's lead product candidate is apraglutide, developed for rare gastrointestinal diseases.

What is the focus of VectivBio as a company?

VectivBio focuses on innovative treatments for severe rare conditions.

VECT

NASDAQ:VECT

VECT Rankings

VECT Latest News

VECT Stock Data

1.06B
59.98M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link